Table 4. . Monoclonal antibodies in newly diagnosed multiple myeloma.
| Author (year) study design | Number of patients | Antibody | Target | Dose | Number of cycles | Regimen | Outcome | Ref. |
|---|---|---|---|---|---|---|---|---|
| San-Miguel et al. (2014) Phase II | 54 | Placebo | IL-6 | 11 mg/kg siltuximab | 9 | VMP | ORR = 80%, CR = 22%, PR = 57%, VGPR = 51%, MR = 8%, PD = 0% | [39] |
| 52 | Siltuximab | Siltuximab + VMP | ORR = 88%, CR = 27%, PR = 61%, VGPR = 71%, MR = 2%, PD = 0% | |||||
| Shah et al. (2016) Phase I/II | 11 (9 REP) | Siltuximab | IL-6 | 8.3–11 mg/kg | 4 | Siltuximab + RVD | ORR = 90.9%, CR = 9.1%, VGPR = 45.5%, PR = 36.45 | [40] |
| Baz et al. (2007) Phase II | 45 | Rituximab + MP | CD20 | 375 mg/m2 | 3 | Rituximab + MP | CR = 0, PR = 58%, MR = 13%, SD = 18%, PD = 11% | [75] |
CR: Complete response; MR: Minimal response; MP: Melphalan, prednisone; ORR: Objective response rate; PD: Progressive disease; PR: Partial response; REP: Response evaluable patient; RVD: Lenalidomide, bortezomib, dexamethasone; VGPR: Very good partial response; VMP: Bortezomib, melphalan and prednisone.